Hello Soju, the world’s premier soju seltzer and ultra-premium spirit—and the shining star of The Hello Group—has successfully raised $6,800,000 in its latest funding round, marking a transformative moment in its growth journey. With its irresistible #SOJUlicious twist, Hello Soju is redefining the beverage landscape by blending tradition with contemporary innovation, and this new capital injection will accelerate its mission to become a household name in the competitive drinks market. The funds secured will be strategically deployed to scale production capacities, allowing Hello Soju to meet surging consumer demand while exploring new, exciting product variants. Additionally, a significant portion of the investment will be allocated toward expanding its market presence both domestically and internationally, ensuring that the unique flavor profile and premium quality of its soju seltzer reach a broader audience. The company also plans to invest in research and development initiatives, further refining its product lineup to cater to evolving consumer tastes and emerging lifestyle trends. This bold financial backing not only underscores the confidence that investors have in the brand's disruptive approach but also reaffirms Hello Soju’s commitment to excellence and innovation. As The Hello Group continues to push the boundaries of quality and taste, this infusion of capital marks a pivotal step forward in solidifying its status as a leader in the ultra-premium spirit category. With a clear vision and robust business strategy, Hello Soju is all set to toast in style—serving refreshing experiences that combine heritage, passion, and the unmistakable allure of being truly #SOJUlicious.
Hello Soju’s $6.8M Boost: Fueling the #SOJUlicious Revolution in Ultra-Premium Spirits
Get the full Hello Soju company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Anveshan
We are a food-tech startup aiming to provide high quality deeply traceable food products. We leverage technologies based on image processing, spectroscopy, blockchain and IOT to provide the best quality food products made traditionally.
$12.7M Series b
today
Caseway
We are the only enterprise AI form platform that replaces internal R&D and manual workflows by building and maintaining fully integrated automation systems, aligned to your data, your processes, and your long-term success. For document-intensive, compliance-driven organizations in regulated industries like insurance, education, finance, healthcare, and government Compelling reason to buy: Who need AI and automation tailored to their unique forms, workflows, and security environment, without having to shoulder R&D risk or manage AI development internally Product category: Our product is an enterprise document form platform Key benefit: That delivers a fully integrated, continuously improving automation system, built and maintained by experts, without upfront AI build costs Key differentiation: Our product is custom-built for each client’s systems and documents, fully integrated and continuously improved through a long-term partnership model, we maintain, debug, adapt, and align incentives to make it work in the real world.
$1.5M Pre-seed
today
Kubera Health
Kubera’s mission is to power a payment ecosystem where contracts are honored, care is rewarded, and waste is eliminated. We deliver contract and payment intelligence that unifies policies, terms, and claims data into one trusted platform — helping healthcare organizations and their partners build fairer contracts, ensure payments flow as intended, and align incentives across the care ecosystem. As healthcare shifts toward new reimbursement models and risk-sharing arrangements, Kubera is building the payment-intelligence backbone that enables multiple parties to adapt faster, protect margins, and dedicate more resources to patient care.
$6.5M Seed
today
Psilera
Psilera is a biotechnology company founded by scientists dedicated to finding better therapeutics for neurological conditions like dementia, addiction, and mental health disorders. Since 2019, Psilera has been focused on early-stage drug discovery & development with a dynamic team of experts in synthetic chemistry, pharmacology, clinical development, and business development.
$8.8M Seed
today
Abstract
Abstract is a venture capital firm based in San Francisco with $1.5 billion in assets under management. We are sector-agnostic, focused on seed and early stage founders. Our reputation among founders is built on fierce loyalty, unparalleled connections, and a relentless drive to help them win.
$59.0M Series a
today